Zelpultide alfa

N/A

Report date: 2026/05/13 20:02:10

Base Information

Drug NameZelpultide alfa
Drug Alias NamerhSP-DAT-100
ClassificationBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionCell membrane permeability enhancersPulmonary surfactant-associated protein D replacement
TargetsPulmonary surfactant-associated protein D
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Community Acquired PneumoniaRespiratory Distress Syndrome, Adult +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesPoland +[9] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesAirway Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesAirway Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Community Acquired PneumoniaRespiratory Distress Syndrome, Adult +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A